Open AccessA non‐selective endothelin receptor antagonist bosentan modulates kinetics of bone marrow‐derived cells in ameliorating pulmonary hypertension in mice
Author(s) -
Kato Taichi,
Mitani Yoshihide,
Masuya Masahiro,
Maruyama Junko,
Sawada Hirofumi,
Ohashi Hiroyuki,
Ikeyama Yukiko,
Otsuki Shoichiro,
Yodoya Noriko,
Shinohara Tsutomu,
Miyata Eri,
Zhang Erquan,
Katayama Naoyuki,
Shimpo Hideto,
Maruyama Kazuo,
Komada Yoshihiro,
Hirayama Masahiro
Publication year - 2020
Publication title -
pulmonary circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.791
H-Index - 40
ISSN - 2045-8940
DOI - 10.1177/2045894020919355
Subject(s) - bosentan , medicine , bone marrow , pulmonary hypertension , stromal cell , endocrinology , endothelin receptor , receptor
The aim of this study was to investigate whether a dual endothelin receptor antagonist bosentan modulates the kinetics of bone marrow‐derived stem cells in inhibiting the development of pulmonary hypertension. Bone marrow chimeric mice, transplanted with enhanced green fluorescent protein (eGFP)‐positive bone marrow mononuclear cells, were exposed to hypobaric hypoxia or kept in the ambient air, and were daily treated with bosentan sodium salt or saline for 21 days. After the treatment period, right ventricular pressure was measured and pulmonary vascular morphometry was conducted. Incorporation of bone marrow‐derived cells was analyzed by immunohistochemistry. Gene expression and protein level in the lung tissue were evaluated by quantitative real‐time PCR and western blotting, respectively. The results showed that, in hypoxic mice, right ventricular pressure and the percentage of muscularized vessel were increased and pulmonary vascular density was decreased, each of which was reversed by bosentan. Bone marrow‐derived endothelial cells and macrophages in lungs were increased by hypoxia. Bosentan promoted bone marrow‐derived endothelial cell incorporation but inhibited macrophage infiltration into lungs. Quantitative real‐time PCR analysis revealed that interleukin 6, stromal cell‐derived factor‐1, and monocyte chemoattractant protein‐1 were upregulated by hypoxia, in which interleukin 6 and monocyte chemoattractant protein‐1 were downregulated and stromal cell‐derived factor‐1 was upregulated by bosentan. Protein level of endothelial nitric oxide synthase (eNOS) in the whole lung was significantly upregulated by hypoxia, which was further upregulated by bosentan. Bosentan modulated kinetics of bone marrow‐derived ECs and macrophages and related gene expression in lungs in ameliorating pulmonary hypertension in mice. Altered kinetics of bone marrow‐derived stem cells may be a novel mechanism of the endothelin receptor blockade in vivo and confer a new understanding of the therapeutic basis for pulmonary hypertension.